Table 1 Baseline characteristics of stages II/III gastric cancer patients aged <75 years with or without adjuvant chemotherapy
Adjuvant chemotherapy | P value | ||
|---|---|---|---|
With n (%) | Without n (%) | ||
Number of patients | 98 | 44 | |
Age (year), median ± SDa | 60.0 ± 9.3 | 64.7 ± 10.8 | 0.141 |
Gender, M/F | 60/38 | 29/15 | 0.708 |
Smoking | 38 (38.8) | 17 (38.6) | 1.000 |
Alcohol drinking | 30 (30.6) | 14 (31.8) | 1.000 |
History of gastric operation | 2 (2.0) | 4 (9.1) | 0.074 |
Location | 0.371 | ||
GEJ | 11 (11.2) | 6 (13.6) | |
Stomach | 87 (88.8) | 38 (86.4) | |
PS | |||
0, 1 | 93 (94.9) | 40 (90.9) | 0.459 |
2, 3 | 5 (5.1) | 4 (9.1) | |
Preoperative CEA (ng/ml), median ± SDa | 1.9 ± 6.8 | 2.3 ± 25.2 | 0.063 |
Preoperative CA19-9 (U/ml), median ± SDa | 10.8 ± 88.7 | 7.4 ± 964.0 | 0.331 |
Tumor size | 0.701 | ||
T1 | 4 (4.1) | 0 (0.0) | |
T2 | 8 (8.2) | 4 (9.1) | |
T3 | 49 (50.0) | 26 (59.1) | |
T4 | 37 (37.7) | 14 (31.8) | |
LN involvement | |||
N0 | 13 (13.3) | 11 (25.0) | 0.040 |
N1 | 10 (10.2) | 9 (20.5) | |
N2 | 34 (34.7) | 6 (13.6) | |
N3 | 41 (41.8) | 18 (40.9) | |
Differentiation | 0.820 | ||
Well/moderate | 20 (20.4) | 9 (20.5) | |
Poor | 78 (79.6) | 35 (79.5) | |
Signet ring cell | 43 (47.3) | 21 (47.7) | 0.705 |
Lymphovascular permeation | 83 (84.7) | 33 (75.0) | 0.312 |
Perineural invasion | 83 (84.7) | 30 (68.2) | 0.053 |
HP | 0.467 | ||
Positive | 41/72 (56.9) | 10/21 (47.6) | |
Negative | 31/72 (43.1) | 11/21 (52.4) | |